683 Capital Management LLC Has $3.15 Million Holdings in Immunomedics, Inc. (IMMU)

683 Capital Management LLC reduced its stake in shares of Immunomedics, Inc. (NASDAQ:IMMU) by 30.8% in the third quarter, according to its most recent filing with the SEC. The fund owned 225,000 shares of the biopharmaceutical company’s stock after selling 100,000 shares during the period. 683 Capital Management LLC owned approximately 0.15% of Immunomedics worth $3,146,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Iguana Healthcare Management LLC lifted its holdings in shares of Immunomedics by 5.3% during the 3rd quarter. Iguana Healthcare Management LLC now owns 500,000 shares of the biopharmaceutical company’s stock worth $6,990,000 after acquiring an additional 25,000 shares during the last quarter. California Public Employees Retirement System lifted its holdings in shares of Immunomedics by 33.0% during the 3rd quarter. California Public Employees Retirement System now owns 154,647 shares of the biopharmaceutical company’s stock worth $2,162,000 after acquiring an additional 38,347 shares during the last quarter. Lyon Street Capital LLC bought a new stake in shares of Immunomedics during the 3rd quarter worth $2,097,000. Nicholas Investment Partners LP bought a new stake in shares of Immunomedics during the 3rd quarter worth $4,673,000. Finally, Schwab Charles Investment Management Inc. lifted its holdings in shares of Immunomedics by 150.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 468,380 shares of the biopharmaceutical company’s stock worth $6,548,000 after acquiring an additional 281,032 shares during the last quarter. 76.32% of the stock is owned by institutional investors.

In other Immunomedics news, Director Venbio Select Advisor Llc bought 1,150,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The shares were bought at an average price of $10.39 per share, for a total transaction of $11,948,500.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Brian A. Markison sold 8,390 shares of Immunomedics stock in a transaction on Monday, November 20th. The stock was sold at an average price of $11.89, for a total transaction of $99,757.10. Following the completion of the transaction, the director now owns 99,178 shares in the company, valued at approximately $1,179,226.42. The disclosure for this sale can be found here. 6.60% of the stock is owned by company insiders.

IMMU has been the subject of a number of research analyst reports. Jefferies Group set a $11.00 price objective on shares of Immunomedics and gave the stock a “buy” rating in a report on Thursday, August 17th. BidaskClub upgraded shares of Immunomedics from a “hold” rating to a “buy” rating in a research report on Wednesday, August 23rd. Zacks Investment Research upgraded shares of Immunomedics from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Wednesday, October 4th. Finally, ValuEngine cut shares of Immunomedics from a “hold” rating to a “sell” rating in a research report on Monday, December 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. Immunomedics currently has an average rating of “Buy” and an average price target of $15.33.

Immunomedics, Inc. (NASDAQ:IMMU) opened at $12.41 on Friday. Immunomedics, Inc. has a 52-week low of $3.30 and a 52-week high of $14.48. The company has a debt-to-equity ratio of -0.29, a current ratio of 0.74 and a quick ratio of 0.74.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright and trademark laws. The correct version of this news story can be read at https://www.com-unik.info/2017/12/15/683-capital-management-llc-has-3-15-million-holdings-in-immunomedics-inc-immu.html.

About Immunomedics

Immunomedics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

What are top analysts saying about Immunomedics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Immunomedics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit